Promise distributes paid release citing July advisory vote

Promise, a Scottsdale, Arizona telehealth platform, distributed a press release through PR Newswire on September 8, 2026, stating that the FDA Pharmacy Compounding Advisory Committee voted 8-6-1 to recommend adding BPC-157 free base and acetate to the Section 503A Bulks List. The advisory vote occurred on July 23, 2026, more than six weeks before the company published its analysis.

The release acknowledges that the committee recommendation is non-binding and did not complete FDA rulemaking. The agency has not issued a proposed rule, opened a public comment , or published a final rule placing BPC-157 on the 503A Bulks List.

Promise, founded in 2026, describes itself as a doctor-guided telehealth platform providing access to peptide therapy, weight management, and hormone care through licensed-provider review. The company lists BPC-157 among its compounded peptide programs, according to the press release.

The statutory boundary remains unchanged

The Pharmacy Compounding Advisory Committee does not approve drugs. Its statutory function is to advise FDA on which bulk drug substances may be eligible for use in compounding under Section 503A. A favorable vote is a recommendation, not a regulatory clearance.

BPC-157 is not FDA-approved. Compounded preparations are not FDA-approved drugs. The agency's rulemaking process, which typically spans 12 to 24 months, has not yet begun for this substance. Legal compounding of BPC-157 cannot occur until FDA completes notice-and-comment rulemaking and publishes a final rule.

The distinction carries practical weight. Telehealth platforms that market compounded peptides based on an advisory vote risk misbranding claims if their communications imply FDA endorsement. Under 21 CFR 216.23(d), representing a compounded drug as FDA-approved is a prohibited act.

Earlier coverage documented how the advisory vote left BPC-157 in regulatory limbo. The practical distinction is easier to assess through the rules governing 503A and 503B compounding pharmacies, not a clinic's interpretation of a committee recommendation. Readers can also compare the claim against the current FDA-approved peptide drug list; BPC-157 is not an approved drug.

What remains unresolved

The release does not change the legal status of BPC-157. FDA career scientists recommended against listing all seven peptides considered at the July meeting, citing a near-total absence of human clinical trial data for injectable routes. For BPC-157 specifically, the only human study identified was a conference abstract involving approximately 46 patients using an enema formulation, not injections.

The agency is not bound by the committee vote. FDA must now decide whether to initiate rulemaking for BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax. Until a final rule publishes, the substance remains outside the 503A Bulks List and unapproved for compounding.